HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings

Key Points

• HC Wainwright raised its EPS outlook, cutting projected 2026 losses (Q2 2026 now ($0.33) vs prior ($0.44)) and modeling a return to profitability by FY2028–FY2029 (FY2028 $1.17; FY2029 $2.59).
• Syndax beat Q1 EPS estimates (reported $(0.48) vs $(0.59) expected) and posted revenue of $64.9M (up 224% year‑over‑year), but the company remains unprofitable with negative ROE and net margin.
• Market view is cautiously bullish: analysts average a "Moderate Buy" with a $40.50 consensus target while shares trade around $20, and insiders have sold roughly 30,063 shares in the last 90 days.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Syndax Pharmaceuticals in a research note issued to investors on Friday, May 1st. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their prior estimate of ($0.44). The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.13) EPS, FY2028 earnings at $1.17 EPS and FY2029 earnings at $2.59 EPS.

A number of other analysts have also commented on SNDX. Wall Street Zen upgraded Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, March 8th. Jefferies Financial Group reiterated a "buy" rating and issued a $40.00 price objective (down from $48.00) on shares of Syndax Pharmaceuticals in a research report on Monday, March 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Syndax Pharmaceuticals in a research report on Friday, March 27th. Barclays lifted their price objective on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a research report on Friday. Finally, JPMorgan Chase & Co. lifted their price objective on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an "overweight" rating in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.50.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $19.96 on Tuesday. The business has a fifty day moving average of $23.03 and a 200-day moving average of $20.43. The company has a debt-to-equity ratio of 5.32, a quick ratio of 4.12 and a current ratio of 4.40. The firm has a market cap of $1.76 billion, a PE ratio of -7.15 and a beta of 0.42. Syndax Pharmaceuticals has a twelve month low of $8.58 and a twelve month high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative return on equity of 216.23% and a negative net margin of 111.88%.The company had revenue of $64.86 million during the quarter, compared to analyst estimates of $69.76 million. During the same period last year, the company posted ($0.98) earnings per share. The firm's quarterly revenue was up 224.3% compared to the same quarter last year.

Insider Activity

In other news, CFO Keith A. Goldan sold 3,410 shares of the business's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $71,712.30. Following the completion of the transaction, the chief financial officer directly owned 140,429 shares in the company, valued at approximately $2,953,221.87. The trade was a 2.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Metzger sold 17,159 shares of the business's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the transaction, the chief executive officer owned 491,690 shares of the company's stock, valued at $10,340,240.70. The trade was a 3.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,063 shares of company stock valued at $628,332 over the last 90 days. Corporate insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its position in shares of Syndax Pharmaceuticals by 2,698.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company's stock worth $55,000 after buying an additional 2,564 shares during the period. Larson Financial Group LLC grew its position in shares of Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company's stock worth $45,000 after buying an additional 1,922 shares during the period. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $53,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Syndax Pharmaceuticals by 26.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company's stock worth $89,000 after buying an additional 893 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $66,000.

More Syndax Pharmaceuticals News

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright materially raised near- and long-term EPS assumptions, trimming projected losses for 2026 and forecasting a path to profitability in later years. The firm’s analyst A. Maldonado now models FY2026 EPS of ($1.16) (prior -$1.66), Q2 2026 ($0.33) from ($0.44), Q3 2026 ($0.21) from ($0.38), and Q4 2026 ($0.13) from ($0.34). They also lifted FY2028 to $1.17 (from $0.91) and FY2029 to $2.59 (from $2.14). This set of upgrades signals faster revenue/profit ramp in the model and supports upside to the stock. MarketBeat SNDX
• Positive Sentiment: AmericanBankingNews published a bullish piece summarizing HC Wainwright’s longer-term upside (FY2030 outlook), reinforcing investor attention on SNDX’s modeled return-to-profitability beyond 2028. HC Wainwright Has Bullish Outlook for SNDX FY2030 Earnings
• Negative Sentiment: Offsetting the mostly upward revisions, HC Wainwright slightly lowered its FY2027 EPS forecast to ($0.13) from ($0.08), indicating some timing uncertainty in the firm’s model between the near-term recovery and later profitability — a modest negative for pacing expectations. MarketBeat SNDX

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.